Evaluation of a high dose cyclophosphamide regimen in childhood tumors

This is the authors' abstract. We don't add key points for this paper.

Cyclophosphamide was given to children with a variety of tumors in a dose of 10 mg/kg/day to the development of a median leukocyte count of 1100 to 1600 cells/mm.3 The dose was tolerated with safety for a median of 9–14 consecutive days in 31 patients given 87 courses. This regimen significantly reduced tumor volume in patients with neuroblastoma, rhabdomyosarcoma, Wilms tumor, Ewing's tumor, malignant lymphoma, and osteogenic sarcoma. A satisfactory antineoplastic effect was seen in 2 patients who were resistant to cyclophosphamide in conventional dosages. The data indicate that more satisfactory tumor response can be obtained by more aggressive use of cyclophosphamide than is generally employed.